Logo

American Heart Association

  10
  0


Final ID: MDP775

ATP Citrate Lyase Supports Cardiac Function and NAD+/NADH Balance And Is Depressed in Human Heart Failure

Abstract Body (Do not enter title and authors here): Background: ATP-citrate lyase (ACLY) is a cytosolic enzyme that plays a prominent role in lipogenesis and lipid bilayer synthesis. It is prominently expressed in liver, adipocytes, and highly proliferative cancer cells. Bempaproic acid, an ACLY inhibitor that requires hepatic activation, is currently approved for hyperlipidemia, and direct inhibitors are being pursued for treating cancer and metabolic associated disorders. The latter increasingly overlaps with myocardial disease, yet the impact ACLY inhibition has on cardiomyocytes or the heart remains largely unknown.
Methods: Cardiomyocytes, ex-vivo beating hearts, and in vivo hearts were studied using a selective ACLY inhibitor (BMS303141, ACLYi) or gene-targeted suppression. Metabolic fate mapping, gene/protein expression, and physiological effects, cytotoxicity, and redox and NAD+/NADH regulation were determined. Mice with reduced cardiac ACLY by AAV9-acly-shRNA or cardiomyocyte-selective inducible knockdown (cmAcly-KD) were studied.
Results: U13C-glucose tracing identified an ACLY-dependent circuit involving ACLY metabolism of cytosolic citrate that becomes converts to malate and then moves back into mitochondria to bypass NADH-generating components of the tricarboxylic acid cycle. Acute inhibition of ACLY (ACLYi) caused dose-dependent myocyte cytotoxicity, but had no effect on fibroblasts. ACLYi acutely depressed myocyte and intact heart function, while hearts with chronically reduced Acly by AAV9-shRNA exhibited ventricular dilation and reduced function. Hearts with cmAcly-KD had reduced exertional capacity, and an exacerbated maladaptive response to sustained pressure overload. ACLYi in vitro and in vivo depressed NAD+/NADH ratio, and its restoration by exogenous NAD reversed both in vitro cytotoxicity and in vivo cardiac dysfunction. ACLY gene and protein expression are reduced in human failing myocardium, with greater transcriptional depression in patients with obesity and heart failure with preserved ejection fraction.
Conclusions: ACLY supports basal cardiomyocyte and cardiac function through maintenance of the NAD+/NADH balance, and is particularly important in settings of hemodynamic stress
  • Meddeb, Mariam  ( The Johns Hopkins University , Baltimore , Maryland , United States )
  • Paolocci, Nazareno  ( Johns Hopkins Medical Institutions , Baltimore , Maryland , United States )
  • Hahn, Virginia  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Sharma, Kavita  ( Johns Hopkins University SOM , Baltimore , Maryland , United States )
  • Pearce, Erika  ( The Johns Hopkins University , Baltimore , Maryland , United States )
  • Kass, David  ( JOHNS HOPKINS MEDICAL INST , Baltimore , Maryland , United States )
  • Koleini, Navid  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Jun, Seungho  ( The Johns Hopkins University , Baltimore , Maryland , United States )
  • Keykhaei, Mohammad  ( The Johns Hopkins University , Baltimore , Maryland , United States )
  • Farshidfar, Farnaz  ( The Johns Hopkins University , Baltimore , Maryland , United States )
  • Zhao, Liang  ( The Johns Hopkins University , Baltimore , Maryland , United States )
  • Kwon, Seoyoung  ( Johns Hopkins , Baltimore , Maryland , United States )
  • Lin, Brian  ( The Johns Hopkins University , Baltimore , Maryland , United States )
  • Keceli, Gizem  ( Johns Hopkins School of Medicine , Baltimore , Maryland , United States )
  • Author Disclosures:
    Mariam Meddeb: DO NOT have relevant financial relationships | Nazareno Paolocci: No Answer | Virginia Hahn: DO NOT have relevant financial relationships | Kavita Sharma: DO have relevant financial relationships ; Consultant:Alleviant:Active (exists now) ; Consultant:Eli Lily:Active (exists now) ; Consultant:Rivus:Active (exists now) ; Consultant:NovoNordisk:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Edwards LifeSciences:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Bayer:Active (exists now) | Erika Pearce: No Answer | David Kass: DO NOT have relevant financial relationships | Navid Koleini: No Answer | Seungho Jun: No Answer | Mohammad Keykhaei: No Answer | Farnaz Farshidfar: No Answer | Liang Zhao: DO NOT have relevant financial relationships | Seoyoung Kwon: No Answer | Brian Lin: DO NOT have relevant financial relationships | Gizem Keceli: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Novel Multiorgan and Intracellular Mechanisms of Heart Failure

Sunday, 11/17/2024 , 11:10AM - 12:25PM

Moderated Digital Poster Session

More abstracts on this topic:
A Two-Hit HFpEF-like Mouse Model with Accelerated Disease Onset

Nehra Sarita, Selvam Sabariya, Anand Amit, Luettgen Joseph, Gulia Jyoti, Dokania Manoj, Gupta Ankit, Garcia Ricardo, Dudhgaonkar Shailesh, Mazumder Tagore Debarati, Ck Neethu, Wagh Somnath, Kale Prajakta

Dual Targeting CXCR4 and CXCR7 Prevents Doxorubicin-Induced Cardiotoxicity by Eliminating Cardiac Inflammation and Preserving Cardiomyocyte Function

Hui Xiaodan, Tan Yi, Gu Chunjie, Abdelbaset-ismail Ahmed, Xu Jianxiang, Tse William, Raj Ashok, Deng Zhongbin, Zhu Wuqiang, Cai Lu

More abstracts from these authors:
Integrated Multi-Omics Myocardial Analysis Suggests Impaired Alternative Fuel Utilization in Heart Failure with Preserved Ejection Fraction

Keykhaei Mohammad, Koleini Navid, Meddeb Mariam, Tajdini Masih, Mulligan Abigail, Sharma Kavita, Kass David, Hahn Virginia

Predictors of Mortality and Hospitalization in Heart Failure with Preserved Ejection Fraction with Low NT-proBNP Levels

Tajdini Masih, Jani Vivek, Tanacli Radu, Keykhaei Mohammad, Hahn Virginia, Sharma Kavita

You have to be authorized to contact abstract author. Please, Login
Not Available